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Background. High-dose rifampicin may improve outcomes of tuberculous meningitis (TBM). Little safety or pharmacokinetic 
(PK) data exist on high-dose rifampicin in human immunodeficiency virus (HIV) coinfection, and no cerebrospinal fluid (CSF) PK 
data exist from Africa. We hypothesized that high-dose rifampicin would increase serum and CSF concentrations without excess 
toxicity.
Methods. In this phase II open-label trial, Ugandan adults with suspected TBM were randomized to standard-of-care control 
(PO-10, rifampicin 10 mg/kg/day), intravenous rifampicin (IV-20, 20 mg/kg/day), or high-dose oral rifampicin (PO-35, 35 mg/kg/
day). We performed PK sampling on days 2 and 14. The primary outcomes were total exposure (AUC0–24), maximum concentration 
(Cmax), CSF concentration, and grade 3–5 adverse events.
Results. We enrolled 61 adults, 92% were living with HIV, median CD4 count was 50 cells/µL (interquartile range [IQR] 46–56). 
On day 2, geometric mean plasma AUC0–24hr was 42.9·h mg/L with standard-of-care 10 mg/kg dosing, 249·h mg/L for IV-20 and 
327·h mg/L for PO-35 (P < .001). In CSF, standard of care achieved undetectable rifampicin concentration in 56% of participants 
and geometric mean AUC0–24hr 0.27 mg/L, compared with 1.74 mg/L (95% confidence interval [CI] 1.2–2.5) for IV-20 and 2.17 mg/L 
(1.6–2.9) for PO-35 regimens (P < .001). Achieving CSF concentrations above rifampicin minimal inhibitory concentration (MIC) 
occurred in 11% (2/18) of standard-of-care, 93% (14/15) of IV-20, and 95% (18/19) of PO-35 participants. Higher serum and CSF 
levels were sustained at day 14. Adverse events did not differ by dose (P = .34).
Conclusions. Current international guidelines result in sub-therapeutic CSF rifampicin concentration for 89% of Ugandan TBM 
patients. High-dose intravenous and oral rifampicin were safe and respectively resulted in exposures ~6- and ~8-fold higher than 
standard of care, and CSF levels above the MIC.
Keywords.  tuberculous meningitis; rifampicin; intensified therapy; HIV; TBM.
Tuberculous meningitis (TBM) is the second leading cause 
of adult meningitis in sub-Saharan Africa [1, 2], yet to our 
knowledge no interventional clinical trials have been con-
ducted in African adults with TBM. TBM treatment is 
extrapolated from pulmonary TB treatment, using rifampicin 
dosed at 600 mg (8–12 mg/kg/day). The trials conducted in 
the 1970–80s did not pursue substantially higher doses of ri-
fampicin (Rifampin®), largely due to its cost in that era [3]. 
Rifampicin is highly bactericidal and has important steril-
izing activity, and low plasma rifamycin exposures have been 
linked to poor treatment outcomes and the evolution of re-
sistance [4–9]. A growing body of evidence from animal and 
clinical studies in pulmonary TB suggests that high-dose ri-
fampicin accelerates bacillary clearance, kills persister organ-
isms, and the maximum tolerated dose in humans is ~40 mg/
kg/day [10–14].
Inadequate central nervous system (CNS) drug penetration 
may be an important contributory factor to TBM mortality. 
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Rifampicin is highly protein-bound, so only ~5% of plasma 
rifampicin penetrates into cerebrospinal fluid (CSF). With 
10 mg/kg/day dosing, the majority of TBM patients have unde-
tectable rifampicin in their CSF [15, 16]. A series of TBM trials 
have tested higher doses, with a survival benefit observed with 
intravenous rifampicin at 13  mg/kg/day in Indonesia but not 
with oral 15 mg/kg/day in Vietnam [15, 17]. As there is first-
pass (gut and hepatic) metabolism of oral rifampicin, higher 
oral dosing of 20 and 30 mg/kg/day has recently been explored 
in Indonesia. Meta-analysis of the Indonesian data demon-
strated a strong relationship between rifampicin total exposure 
and survival in 148 predominantly HIV-negative TBM patients 
[18–20]. Yet pharmacokinetics (PK) data from Asia cannot 
necessarily be extrapolated to African populations due to dif-
ferences in HIV serostatus, comorbidities, body size, pharma-
cogenomics, and drug-drug interactions with HIV medicines 
[21, 22].
We conducted the first randomized clinical trial in African 
adults with suspected TBM to test the hypothesis that high-dose 
rifampicin, administered orally or intravenously, is safe and in-
creases blood and CSF exposures and attainment of PK targets 
in a Ugandan population consisting predominantly of people 
living with HIV (PLHIV).
METHODS
Study Population and Setting
We recruited participants from Kiruddu Hospital in Kampala 
and Mbarara Regional Referral Hospital in Mbarara, Uganda, 
as per a published protocol (ISRCTN42218549) [23]. We 
obtained consent from adults (≥18  years) with suspected 
TBM and either microbiological confirmation (eg, CSF Xpert 
MTB/Rif Ultra) or low CSF glucose (CSF:plasma ratio <50% 
or CSF glucose <65 mg/dL [<3.6 mmol]) with TBM treatment 
planned. We excluded those with jaundice or known cirrhosis; 
>3 doses of TB treatment within the previous 3 days; allergy 
to first-line TB medicines; rifampicin-resistant M.  tubercu-
losis; cryptococcosis; relevant drug-drug interaction (eg, HIV 
protease inhibitors); pregnant or breastfeeding; known por-
phyria; creatinine clearance <10 mL/min; or unable to attend 
follow-up visits.
Randomization
Participants were randomly assigned in a 1:1:1 ratio to 1 of 3 
trial arms. The randomization list was generated by a computer-
generated permutated block randomization algorithm of dif-
ferent sized blocks using sealed envelopes. Randomization was 
stratified by site and Medical Research Council (MRC) disease 
severity grade (grade I or II/III). To avoid delaying urgent TBM 
treatment, participants were withdrawn and replaced a pos-
teriori if their baseline alanine transaminase (ALT) was >3× 
upper limit of normal (ULN).
Study Treatment
Participants were randomized to 1 of 3 antituberculous therapies: (1) 
IV-20, high-dose intravenous (IV) rifampicin (20 mg/kg/day) admin-
istered over 2 hours, alongside oral isoniazid (5 mg/kg), pyrazinamide 
(25 mg/kg), and ethambutol (20 mg/kg); (2) PO-35, high dose oral 
rifampicin (35  mg/kg/day), administered as standard fixed-dose 
combination antituberculous tablets (RHZE) (containing ~10 mg/kg 
of rifampicin) along with additional 25 mg/kg dose given as 300 mg 
oral rifampicin capsules given for 8 weeks; (3) standard-of-care (con-
trol arm) RHZE tablets (containing ~10 mg/kg/day of rifampicin) 
according to World Health Organization (WHO) weight-bands 
(Supplementary materials). In the IV-20 arm, after 14 days, partici-
pants were switched to 35 mg/kg oral rifampicin through 8 weeks, 
as per PO-35 arm. Study drugs were administered under directly 
observed therapy during hospitalization. Adjunctive corticoster-
oids were given routinely as dexamethasone 0.4 mg/kg/day IV for 
week 1, 0.3 mg/kg/day IV for week 2, and thereafter as oral prednis-
olone 80 mg/day, weaned to a stop over the following 6 weeks [23]. 
Antiretroviral therapy (ART)-naive individuals initiated ART after 
completion of the intensive phase of TB treatment (week 8) in accord-
ance with Ugandan guidelines. In Uganda, tenofovir/lamivudine/
dolutegravir is the preferred first-line ART regimen since 2018; prior 
to that efavirenz was the recommended third agent. PLHIV received 
cotrimoxazole prophylaxis.
Outcome Assessment and Follow-Up
Participants were reviewed daily during hospitalization for 
neurological status and adverse events (AE) ascertainment 
using the Division of AIDS table version 2.1 [24], before being 
discharged around day 14 unless their medical condition war-
ranted prolonged hospitalization. After hospital discharge, out-
patients follow-up occurred at weeks 4, 8, 12, 18, and 24. We 
assessed neurocognitive performance at weeks 8 and 24, as pos-
sible [25, 26]. After 24 weeks, participants were referred to local 
TB services to complete 9–12 months of therapy.
Primary endpoints were (1) pharmacokinetic parameters in 
serum (area under the time concentration curve between 0 and 
24 hours [AUC0–24], maximum concentration [Cmax]) and CSF 
concentration (CCSF); (2) composite safety endpoint during the 
8-week intervention period comprising any of: (a) grade 3–5 AEs 
including drug-induced liver injury; (b) serious AEs (SAEs); or (c) 
discontinuation of rifampicin for >5 days for any cause. Secondary 
endpoints included survival to 8 and 24 weeks, time to normaliza-
tion of consciousness (Glasgow coma scale [GCS = 15]), functional 
status by modified Rankin scale at 8 and 24 weeks, and quantitative 
neurocognitive performance Z score at 8 and 24 weeks.
Pharmacokinetic Analysis
We conducted plasma PK sampling on day 2 (±1) predose and 
2, 4, and 8 hours post-dose. We collected a single CSF sample 
between 2 and 8 hours post-dose with randomized collection 
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windows. On day 14 (±2), we collected a single plasma and 
CSF sample between 2 and 8 hours post-dose. Total rifampicin 
concentrations were analyzed by validated high-performance 
liquid chromatography with ultraviolet detection (HPLC-UV) 
in the Infectious Disease Institute Translational Laboratory 
using an LC-2010C HT system (Shimadzu, Kyoto, Japan). The 
PK parameters Cmax and area-under-the time-concentration 
curve up to 8 hours post-dose (AUC0–8) were determined 
using a standard noncompartmental approach with Phoenix 
WinNonLin (Certara, Princeton, New Jersey, USA) using the 
log-linear trapezoidal rule. The AUC0–24 was determined using 
a published population PK model modified for IV administra-
tion using NONMEM (Icon Development Solutions, Hanover, 
Maryland, USA) [27]. For further methods see Supplemental 
materials.
Statistical Analysis
Sample size was determined following the assumption that PK 
parameters are normally distributed on the log-scale using ri-
fampicin log-transformed Cmax standard deviation derived 
from prior research [15]. PK data from 15 participants per 
arm achieves 90% power to reject the null hypothesis of equal 
means. Participants were categorized according to the uniform 
case definition (definite = microbiologically confirmed, prob-
able = ≥12 points with brain imaging or ≥10 points without 
brain imaging, possible = 6–11 points with imaging or 6–9 
points without imaging, not TBM = <6 points or alternative 
cause identified) [28]. Statistical analysis adhered to the pub-
lished protocol [23] and statistical analysis plan. We followed 
CONSORT guidelines and conducted analyses by intention to 
treat (ITT). We compared the proportions experiencing grade 
3–5 AEs, and the composite safety endpoint during the inter-
vention period, between arms with χ 2 test. Mortality at 8 and 
24 weeks post-randomization was compared between study 
arms using the risk difference from a generalized linear regres-
sion model with binomial distribution and identity link func-
tion. Kaplan-Meier curves were used to compare time to death. 
Participants withdrawn or lost-to-follow-up were censored at 
last contact. We compared mean modified Rankin score at 8 
and 24 weeks between arms using a linear regression model. 
Data were collected using DataFax, and analyses were con-
ducted using Stata version 13.1 (StataCorp, College Station, 
Texas, USA).
Ethical Considerations and Oversight
Written informed consent was obtained from participants or 
their caregiver. The trial was approved by the Research Ethics 
Committees of LSHTM, UK, and Mulago Hospital, Uganda 
National Council of Science and Technology, and Uganda 
National Drug Authority. An independent data safety com-
mittee reviewed accruing data.
RESULTS
Study Population
Between 14 January and 17th December 2019, 61 adults with 
suspected TBM were enrolled, including 31 (51%) with micro-
biologically confirmed TBM (Figure 1). One participant was 
withdrawn (from PO-35, baseline ALT > 3× ULN), and an ad-
ditional participant was enrolled to replace the withdrawal (ran-
domized to the control arm). One participant withdrew consent 
for follow-up. One participant left hospital against medical ad-
vice on day 3 and was lost to follow-up. Baseline characteristics 
are described in Table 1. The majority of participants (56/61, 
92%) were living with HIV with a median CD4 count of 50 
cells/µL (interquartile range [IQR] 46–56), a median HIV viral 
load of 4815 copies/mL, and 20 (33%) were on ART with a me-
dian duration of 36 days (IQR 16–61 days). There were no cases 
of rifampicin-resistant disease identified.
Primary Outcomes
On day 2 in the standard-of-care arm, serum Cmax was 6.0 mg/L 
(95% confidence interval [CI], 4.20–8.68) and AUC0–24 was 42.9 
h × mg/l (95% CI, 29.2–63.0). With IV-20, Cmax increased to 
36.2 mg/L (95% CI, 31.8–41.2) and AUC0–24 increased 5-fold to 
217 h × mg/l (95% CI, 202–306; P < .001 for each comparison 
with standard-of-care arm). In the PO-35 arm, Cmax increased to 
29.3 mg/L (95% CI, 23.0–37.5) and AUC0–24 increased ~8-fold 
to 327 h × mg/l (95% CI, 248–430; P < .001 for each). In CSF, 
with standard-of-care treatment 56% (10/18) of participants 
had undetectable rifampicin (<0.25 mg/L) and geometric mean 
concentration was 0.27  mg/L (95% CI, <.25–.45). CSF rifam-
picin was detectable in all participants in the intensified arms. 
Geometric mean CSF concentrations were ~6-fold higher with 
IV-20 at 1.74 mg/L (95% CI, 1.20–2.53) and 8-fold higher with 
PO-35 at 2.17  mg/L (95% CI, 1.64–2.86; P < .001 for each). 
A CSF concentration > 1 mg/L, the rifampicin minimal inhib-
itory concentration (MIC) for the predominant M. tuberculosis 
strain in Uganda [29], occurred in 11% (2/18) with standard-of-
care treatment, 93% (14/15) with IV-20, and 95% (18/19) with 
PO-35 (P < .001). PK results are further described in Table 2 
and Figure 2.
In the CSF at day 14, when rifampicin autoinduction is ~90% 
established [27], 11% (1/9) of participants in the standard-of-
care arm had detectable rifampicin (>0.25 mg/L), whereas 88% 
(7/8) with IV-20 and 89% (8/9) PO-35 arm had detectable CSF 
levels. Geometric mean CSF concentrations were 0.57  mg/L 
(95% CI, .30–1.11, P = .001) for IV-20 and 0.45 mg/L (95% CI, 
.21–.96, P = .007) for PO-35, compared to 0.15 mg/L (95% CI, 
.10–.23) for standard-of-care treatment.
During the 8-week intervention period, grade 3–5 AEs oc-
curred in 15 (71%) of standard-of-care treatment, 10 (50%) of 
IV-20, and 11 (55%) PO-35 participants (P = .342). No par-
ticipants interrupted rifampicin for >5  days. The composite 
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safety endpoint did not differ between arms (P = .342), Table 
3. The most common grade ≥3 AE, elevated ALT, occurred in 7 
(12%) of participants and was attributed to drug-induced liver 
injury (DILI), which occurred in 4 (19%) participants with 
standard-of-care treatment, 1 (5%) with IV-20, and 2 (10%) 
with PO-35. ALT elevations were grade 3, except one episode 
of grade 4 ALT elevation in the standard-of-care arm. Isolated 
hyperbilirubinemia, a recognized side-effect of rifampicin, oc-
curred in 3 (5%) participants (grade 4) during the intervention.
Secondary Outcomes
Overall, during the 8-week intervention period, 18 (30%) parti-
cipants died: 5/21, 6/20, and 7/20 in the standard-of-care, IV-20, 
and PO-35 arms, respectively. There was no evidence of an asso-
ciation with treatment arm (LR test P-value = .595). By the end 
of the 24-week follow-up period, 24 (39%) of participants had 
died: 7/21, 7/20, and 10/20 in the standard-of-care, IV-20, and 
PO-35 arms, respectively. There was no evidence of association 
with treatment arm (LR test P-value = .333). Kaplan-Meier sur-
vival curves are shown in Figure 3. Mean modified Rankin scores 
(0 = asymptomatic, 6 = dead) at week 8 were 2.06, 1.84, and 
2.30 (P = .75), and at week 24 were 0.86, 0.81, and 1.14, in the 
standard-of-care, IV-20, and PO-35 arms, respectively (P = .85). 
Time to normalization of GCS did not differ compared to the 
standard-of-care arm: IV-20 subdistribution hazard ratio (SHR) 
1.20 (95% CI, .58–2.48; P = .630) and PO-35 0.85 (95% CI, .41–
1.77; P = .658). For further results, see Supplementary materials.
DISCUSSION
In this randomized controlled trial of high-dose rifampicin 
involving predominantly adults living with HIV with sus-
pected TBM, both high-dose intravenous and oral rifampicin 
resulted in a far greater proportion of participants achieving 
CSF levels above the M. tuberculosis MIC of rifampicin when 
compared to standard TB treatment. With the currently 
Figure 1. CONSORT diagram. Abbreviations: LTFU, long-term follow-up, PK, pharmacokinetics.
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WHO-recommended TB therapy, only 1 in 10 people achieved 
a CSF rifampicin concentration above the MIC. As well as 
being rapidly bactericidal, rifampicin is the key sterilizing drug 
in the regimen, so attainment of the rifampicin MIC in the CSF 
should be considered a bare minimum target in TBM.
Importantly, despite the substantial increase in rifampicin 
exposure in the intervention arms, there was no increase in 
toxicity, in line with other studies of largely HIV-negative in-
dividuals [10, 15, 18, 30]. The adverse effects of rifampicin 
are well described and include hypersensitivity reactions 
featuring fever and/or rash, thrombocytopenia, liver toxicity, 
and hyperbilirubinemia. Recent data from PanACEA consor-
tium suggest that rifampicin toxicity is largely idiosyncratic, 
and our findings support the notion that exposure is not a 
driver of toxicity [14]. This is reassuring given that people 
with advanced HIV are at increased risk of drug-related tox-
icity including cutaneous drug reactions, hypersensitivity, liver 
toxicity, and complications relating to polypharmacy and im-
mune reconstitution [21, 22]. Due to the severely unwell na-
ture of the trial population, grade 3–5 AEs were experienced by 
over half (59%, 36/61) the participants but were largely com-
plications of the underlying disease process, and events were 
evenly distributed across arms. Interruption of antituberculous 
therapy is associated with increased mortality from TBM [31]. 
We therefore used a DILI management algorithm in which 
pyrazinamide was interrupted in isolation with regular moni-
toring of liver function tests, allowing other antituberculous 
agents to be continued. This was effective in all occurrences of 
DILI during the intensive phase. We did not observe any im-
pact of high-dose rifampicin on 8- or 24-week mortality, time 
to normalization of conscious level, nor functional outcomes 
by modified Rankin scale. This phase II study was not powered 
for clinical endpoints; thus an adequately powered trial is jus-
tified having established the safety of high-dose rifampicin in 
HIV coinfection.
The rifampicin dosing increases resulted in greater than 
proportional increases in serum and CSF exposure: a 2-fold 
dose-increase administered intravenously resulted in ~6-fold 
increase in exposures, and a 3.5-fold oral dose-increase resulted 
in a ~8-fold increase in exposures. The supra-proportional in-
crease in exposures observed here is attributable to (1) sat-
uration of the beta-esterase metabolizing enzymes and/or 
p-glycoprotein with a reduction in the first-pass effect and 
thereby increased bioavailability of oral drug; (2) saturation 
of the biliary excretion pathway [10, 27]. Rifampicin induces 
its own metabolism, a phenomenon known as clearance 
Table 1. Baseline Characteristics
IV-20 Arm PO-35 Arm Control Arm
N randomized 20 20 21
Age, median (IQR) years 33.5 (25.5–38.5) 32.5 (26.5–38.5) 34.0 (27– 36)
Gender, male N (%) 13.0 (65) 12.0 (60) 9.00 (42.9)
Weight, median (IQR), kg 55 (47.5–58.5) 50.5 (50–55) 50.0 (45–55)
HIV details    
 HIV-positive, N (%) 18.0 (90) 18 (90) 20 (95.2)
 HIV-negative, N (%) 2 (10) 2 (10) 1 (4.80)
Amongst those HIV positive:
CD4 T-cell count, cells/µL 55 (45–59) 50.5 (50–55) 50 (45–55)
HIV viral load, median (IQR) copies/mL 7840 (4014 – 574 462) 6523 (4815 – 92 346) 2334 (945 – 19 316)
Currently receiving ART, N (%) 8 (44) 7 (39) 5 (28)
Antiretroviral therapy duration, median (range), weeks 4 (0 – 62) 3.7 (1.6 – 6.6) 8.7 (0.7 – 196)
MRC TB meningitis grade, n (%)   
I 3 (15) 1 (5) 2 (9.5)
II 13 (65) 16 (80) 12 (57.1)
III 4 (20) 3 (15) 7 (33.3)
Uniform case definition, n (%)    
 Definite (microbiologically confirmed) 8 (40) 12 (60) 11 (52.4)
 Probable 4 (20) 4 (20) 6 (28.6)
 Possible 7 (35) 4 (20) 1 (4.8)
 Not 1 (5) 0 (0) 3 (14.3)
CSF information, median (IQR)   
Opening pressure, mmH20 230 (155–320) 220 (135–300) 135 (100–230)
White cells, cells/ µL) 24 (4–162.5) 4 (4–145) 4 (4–122.5)
Protein, mg/dL 154.5 (105–186) 125 (73–188) 92 (30–164)
Glucose, mg/dL 41 (21–68) 44 (21–66.7) 38 (18–64)
Lactate, mmol/L 8.5 (7.30–9.80) 6.9 (2.9–11.1) 8 (5.2–10.4)
Abbreviations: ART, antiretroviral therapy; CSF, cerebrospinal fluid; HIV, human immunodeficiency virus; IQR, interquartile range; MRC, Medical Research Council; TB, tuberculosis.
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autoinduction, resulting in lower exposure at steady-state. 
Despite this phenomenon, we found that rifampicin con-
centrations in the interventional arms remained higher than 
those in the standard-of-care arm at day 14 when clearance 
autoinduction was established.
In relation to other TBM intensification studies, the day 2 total 
serum rifampicin exposures achieved in the IV-20 and PO-35 arms 
were, respectively, 3- and 4-fold higher than that of the intensified arm 
of the landmark Vietnamese trial by Heemskerk et al (AUC0–24 82.5 h 
× mg/l following rifampicin 15 mg/kg/day) [32]. The total exposure 
achieved with PO-35 (AUC0–24 327 h × mg/l) is comparable to the 
most recent Indonesian phase II trial, which tested rifampicin 30 mg/
kg/day and reported an AUC0–24 of 294 h × mg/l [18]. Owing to the 
difficulty in consistently culturing M. tuberculosis, CSF does not lend 
itself to microbial kill studies. We therefore cannot draw any parallels 
with the bacillary clearance rates in pulmonary TB high-dose rifam-
picin studies, but our data can contribute to a PK-PD model to under-
stand the exposure-response relationship in this population.
Comorbid conditions can impact the PK of antituberculous 
drugs, including HIV infection, which alters rifampicin expo-
sure in the initial days of therapy. Meta-analysis of rifampicin 
PK data from 70 studies including 3477 participants confirmed 
that during the initial days of standard TB treatment rifampicin 
total plasma exposure is reduced in PLHIV (mean AUC0–24 
was 37.2 h × mg/l in living with HIV vs 56.7 h × mg/l in HIV-
negative adults, P = .003), though this difference diminished at 
steady-state [33]. Our participants in the standard-of-care arm 
had a serum geometric mean AUC0–24 of 42.9 h × mg/l, similar 
to the PLHIV and lower than the HIV-negative group in the 
meta-analysis [33]. It is encouraging that despite the study pop-
ulation having advanced HIV, high blood and CSF rifampicin 
exposures were achieved with oral administration of rifampicin 
at 35 mg/kg/day. Critical illness can also alter drug PK, com-
pounded by coma requiring TB drugs to be given via nasogas-
tric tube, and vomiting, all of which may jeopardize effective 
early therapy. It is therefore reassuring that high blood and CSF 
Table 2. Rifampicin Pharmacokinetic Data by Treatment Arm
IV-20 PO-35 Control P valuea
AUC0–8 (h × mg/l)
b     
n observationsc 19 19 20  
 Geometric mean (95% CI) 163 (142–186) 162 (129–203) 30.5 (21.7–42.8) <.001
 Ratio to control 5.33 5.31 …  
 P valued <.001 <.001 …  
AUC0_24 (h × mg/l)
e     
n observations 19 19 21  
 Geometric mean (95% CI) 249 (202–306) 327 (248–430) 42.9 (29.2–63.0) <.001
 Ratio to control 5.80 7.62 …  
 P valued <.001 <.001 …  
Cmax (mg/L)
b     
n observationsg 19 16 17  
 Geometric mean (95% CI) 36.2 (31.8–41.2) 29.3 (23.0–37.5) 6.04 (4.20–8.68) <.001
 Ratio to control 5.99 4.86 …  
 P valued <.001 <.001 …  
 n (%) achieving TDM target of >8 mg/L 20 (100) 20 (100) 10 (47.62) <.0001f
Tmax (hours)     
 Median (range) 2.35 (1.83–3.85) 4.05 (2.17–7.33) 2.83 (2.08– 8.25) .002g
CCSF (mg/L)     
n observations 15 19 18  
 Geometric mean (95% CI) 1.74 (1.20–2.53) 2.17 (1.64–2.86) .27 h (.17– .45) .058
 Ratio to control 6.44 8.00 …  
 P valued <.001 <.001   
 n (%) with detectable CSF level 15 (100) 19 (100) 8 (44) <.001 f
 n (%) with concentration above rifampicin MIC (1 mg/L) 14 (93.3%) 18 (94.7%) 2 (11.1%) <.001 f
 Median (IQR) hours post-dose 4.70 (3.28–5.92) 4.55 (3.08–6.20) 4.83 (3.78–5.5)  
Abbreviations: AUC, area under the curve; CI, confidence interval; CSF, cerebrospinal fluid; IQR, interquartile range; MIC, minimum inhibitory concentration; PK, pharmacokinetics; TDM, 
therapeutic drug monitoring.
a Likelihood ratio P value from general linear regression.
b Standard 2-step noncompartmental analysis on Phoenix WinNonLin. Where concentration was still increasing at the last sampling point it was not possible to determine Cmax.
c AUC0–8 was based on AUC0-last if Tlast was sufficiently close to 8 hours.
d Pairwise comparison between experimental arm and control arm from general linear regression 
e AUC0–24 derived using published population PK model in NONMEM [27]
f P value by χ 2 test.
g P value by Kruskal Wallis test.
h 10 participants had CSF levels below the lower limit of quantification (LLOQ = 0.25mg/l). A value of 50% of the LLOQ was assigned.
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exposures were achieved with oral rifampicin, which is more 
widely available in TB endemic settings and a less complex in-
tervention than intravenous rifampicin.
HIV is central to the incidence of TBM in sub-Saharan Africa 
[34]. The vast majority of the study population (92%) were living 
with HIV under half were on ART, none were virologically sup-
pressed, and median CD4 count was 50 cells/µL. Effective HIV 
treatment reduces the risk of TB by ~80%; therefore, earlier and ef-
fective HIV treatment are key upstream interventions to reduce the 
incidence of TBM [35]. Other important upstream interventions 
include TB preventative therapy and screening for TB prior to ART 
initiation. The rollout of dolutegravir as first-line ART in Uganda 
began in 2018 and may support improved HIV virological suppres-
sion going forward. We dose-adjusted dolutegravir to 50 mg twice 
daily, which is known to be effective with standard rifampicin [36, 
37]. An ongoing study in Uganda is examining the impact of rifam-
picin 35 mg/kg on dolutegravir levels [4].
This study has a number of limitations. Due to inability to stand, 
baseline weight was frequently estimated, potentially introducing 
imprecision in weight-based dosing. Ideally, we would have col-
lected blood and CSF samples at more time points, especially in 
the clearance phase, to allow estimation of elimination rate and 
half-life and CSF Cmax. However, we prioritized participant safety 
and comfort, so restricted blood sampling to daylight hours and 
performed a single PK lumbar puncture. As in many TBM trials, 
microbiological confirmation was only made in half the partici-
pants. Because a minority of TBM patients are culture positive, 
and the complexity of performing rifampicin MIC, the MIC was 
derived from population estimates within the same TB laboratory 
[29, 38]. This phase II study was adequately powered for quantifi-
cation of PK parameters, but due to limited sample size, no con-
clusions about clinical outcomes can be drawn. Lack of PK-PD 
target exposures limits the ability to interpret the translational im-
portance of these data.
This phase II study provides encouraging evidence that in a 
population consisting predominantly of people living with HIV 
high-dose rifampicin increases CSF and serum exposures with 
no additional toxicity. These data, taken together with data from 
Figure 2. A-C Pharmacokinetic parameters on day 2. Distribution of rifampicin. A, Area under the concentration-time curve from 0 to 24 hours post-dose (AUC0–24), (B) max-
imum concentration in plasma (Cmax), (C) CSF concentration (CCSF), the horizontal red line is the Mycobacterium tuberculosis Uganda II MIC of 1 mg/L. The x axis shows the 3 
trial arms: intravenous rifampicin 20 mg/kg, oral rifampicin 35 mg/kg, control rifampicin 10 mg/kg, in combination with standard doses of isoniazid, pyrazinamide, ethambutol, 
and corticosteroids. Red dashed line represents geometric mean concentrations; green dashed lines represent 95% confidence intervals. Abbreviation: CSF, cerebrospinal 
fluid; MIC, minimal inhibitory concentration.
High-dose rifampicin in HIV/TB meningitis • cid 2021:73 (1 September) • 883
Indonesian studies, justify a phase III trial to investigate safety in a 
wider population and determine the impact of high-dose rifam-
picin on death and disability. We look forward to the outcome of a 
number of trials in the pipeline examining high-dose oral rifampicin 
in isolation (ISRCTN15668391), or with adjunctive linezolid and 
aspirin (NCT04145258, NCT03927313). Whether in future the op-
timized TBM treatment regimen will include high-dose rifampicin 
remains to be concluded.
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Supplementary materials are available at Clinical Infectious Diseases online. 
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questions or comments should be addressed to the corresponding author.
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Table 3. Adverse Events by Treatment Arm During the 8-Week Interventional Period
IV-20 (n = 20) PO-35 (n = 20) Control (n = 21) P value
Total number of events N (%) N (%) N (%)  
 Grade 3 6 (30) 6 (30) 12 (57) .12
 Grade 4 3 (15) 4 (20) 4 (19) .91
 Grade 5 5 (25) 7 (35) 5 (24) .68
Neurological event     
 Cerebrovascular accident 2 (10) 1 (5) 1 (4.8)  
 Seizures 1 (5) 2 (10) 2 (9.5)  
 Headache 0 (0) 0 (0.0) 1 (4.8)  
 Hearing loss 0 (0) 1 (5) 0 (0)  
 Neuropathy 0 (0) 0 (0) 1 (4.8)  
 Altered mental status 2 (10) 1 (5) 2 (9.5)  
Generalised     
 Fever 0 (0) 2 (10) 1 (4.8)  
 Rash (Kaposi’s sarcoma) 0 (0) 1 (5) 1 (4.8)  
Gastrointestinal and hepatic    
 Abdominal pain 0 (0) 1 (5.0) 0 (0)  
 Dysphagia 1 (5) 0 (0) 0 (0)  
 Elevated alanine transaminase 1 (5) 2 (10) 4 (19)  
 Elevated bilirubin 1 (5) 0 (0) 2 (9.5)  
Other     
 Anemia 1 (5) 1 (5) 2 (9.5)  
 Hypotension 1 (5) 0 (0) 0 (0)  
 Thrombosis 0 (0) 0 (0) 1 (4.8)  
 Elevated creatinine 1 (5) 1 (5) 1 (4.8)  
 Urinary tract obstruction 0 (0) 1 (5) 0 (0)  
 Respiratory distress 1 (5) 2 (10) 3 (14)  
 Low sodium 1 (5) 1 (5) 0 (0)  
AEs in relation to pre-specified secondary endpoint 
 N (%) with a grade 3–5 AE 10 (50) 11 (55) 15 (71) .343
 N (%) with a serious AE 8 (40) 7 (35) 7 (33) .899
 N (%) of patient with discontinuation of rifampicin for >5 days in week 0–8 0 0 0  
 Composite of 1 or 2 or 3 10 (50) 11 (55) 15 (71.4) .343
Values are N (%). P values by χ 2 test. All serious adverse effects (AEs) were represented within the grade 3–5 AE row and already included in the composite endpoint.
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